6 assets in Cloacogenic Carcinoma

Therapeutic assets addressing Cloacogenic Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Cloacogenic Carcinoma	National Cancer Institute (NCI)	P3	BB (66)
Nivolumab Cloacogenic Carcinoma	National Cancer Institute (NCI)	P3	B (60)
Capecitabine Cloacogenic Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Fludeoxyglucose Cloacogenic Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Fluorouracilum Cloacogenic Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Muamycin Cloacogenic Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)